An **Anti-Chlamydia trachomatis IgM antibody** test detects the early immune response to *Chlamydia trachomatis*, a common bacterial sexually transmitted infection (STI). Because IgM is the first antibody the immune system produces during an infection, its presence in the blood typically indicates a **recent or active infection**.

While highly useful for identifying acute cases, IgM levels naturally decline as the body transitions to long-term immunity (IgG antibodies). Doctors often pair this test with other diagnostics, like PCR swab tests, to confirm active chlamydia, manage potential complications like pelvic inflammatory disease, and ensure accurate, timely treatment.

An **Anti-DNase B (Anti-Deoxyribonuclease B) Serum test** measures antibodies produced by the body in response to a group A *Streptococcus* bacterial infection. While a sore throat is the most common presentation, this specific test is exceptionally valuable for detecting recent **streptococcal skin infections (impetigo)**, where other tests like ASOT can sometimes fail.

Evaluating Anti-DNase B levels helps doctors confirm past strep exposure when investigating delayed, serious complications. These include **acute post-streptococcal glomerulonephritis** (a kidney inflammatory disorder) and **rheumatic fever**, ensuring patients receive the correct, targeted long-term care.

An **Anti-dsDNA (Anti-double-stranded DNA) antibody** test detects autoantibodies that mistakenly target the genetic material inside a person's own cells. This test is highly specific and serving as a hallmark diagnostic marker for **Systemic Lupus Erythematosus (SLE)**, a chronic autoimmune disease.

Because anti-dsDNA levels fluctuate in tandem with disease activity, doctors frequently use this blood test to monitor **lupus flares** and assess the risk of organ damage. Elevated levels are particularly correlated with **lupus nephritis**, a serious complication involving kidney inflammation, making the test vital for managing and tailoring ongoing treatment strategies.

An **Anti-dsDNA Antibody (IFA) Serum** test utilizes Indirect Immunofluorescence Assay (IFA) technology to detect autoantibodies targeting double-stranded DNA. This specialized method often employs *Crithidia luciliae* as a substrate, providing a highly specific substrate (the kinetoplast) to definitively confirm a **Systemic Lupus Erythematosus (SLE)** diagnosis.

By visualizing the fluorescent staining patterns under a microscope, clinicians can accurately differentiate lupus from other autoimmune conditions. Because positive IFA results correlate strongly with active **lupus nephritis**, this serum test serves as a critical biomarker for monitoring disease severity, predicting renal flares, and guiding clinical immunosuppressive therapies.